Search
May 31
Oncology expert Paul Rennert gives an update on Aleta Biotherapeutics and previews some targets at #ASCO24
Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as...
Nov 4, 2023
Aleta Biotherapeutics' Paul Rennert on what he sees is working, and what isn't, at #SITC23
Paul Rennert gives an update on Aleta, and summarizes data at #SITC23 from the IO 2.0, cytokine, TGF beta, Treg, lymphoid, and CAR-T spaces.
Jun 2, 2023
Watching cell therapy innovation at #ASCO23.
Paul Rennert of Aleta Biotherapeutics gives a rundown on the latest in cell therapies and other modalities ahead of #ASCO23.
.png){kind=logo}
